The effects of lovastatin on conventional medical treatment of lower urinary tract symptoms with finasteride.
OBJECTIVE
To explore whether or not statins have any impact on the progression of components of benign prostatic hyperplasia (lower urinary tract symptoms severity, prostate volume and serum prostate specific antigen (PSA) when combined with other agents inhibiting growth of prostate cells.


METHODS
This was a preliminary, clinical study. Eligible patients were aged > 50 yrs, with International Prostate Symptom Score (IPSS) between 9 and 19, total prostate volume (TPV) >40 mL, and serum PSA > 1.5 ng/mL. Patients were divided in two groups: those with and those without lipidemia. After selection, eligible BPH patients with lipidemia (n = 18) were prescribed lovastatin 80 mg daily and finasteride 5 mg daily, while eligible patients without lipidemia (n = 15) were prescribed only finasteride 5 mg daily. IPSS, TPV and serum PSA were evaluated at end point (4 months).


RESULTS
There was no difference between the two groups on the primary end point of mean change from baseline in IPSS (p = 0.69), TPV (p = 0.90) and PSA (p = 0.16) after 4 months of treatment.


CONCLUSIONS
Short-term lovastatin treatment does not seem to have any effect on IPSS, TPV and PSA in men with prostatic enlargement due to presumed BPH.
Stamatiou
Konstantinos N
KN
Department of Urology, General Hospital of Thebes, Greece. stamatiouk@gmail.com
Zaglavira
Paraskevi
P
Skolarikos
Andrew
A
Sofras
Frank
F
D000368:Aged; D000924:Anticholesteremic Agents / Q000008:administration & dosage*; D018450:Disease Progression; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000008:administration & dosage*; D018120:Finasteride / Q000008:administration & dosage*; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications / Q000188:drug therapy; D008148:Lovastatin / Q000008:administration & dosage*; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood; D011470:Prostatic Hyperplasia / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D012720:Severity of Illness Index; D016896:Treatment Outcome
D000924:Anticholesteremic Agents; D004791:Enzyme Inhibitors; D018120:Finasteride; D008148:Lovastatin; D017430:Prostate-Specific Antigen